According to the NIHR* Severe chronic pain has “adverse effects on all aspects of general health as well as on daily life” and reduces an individual’s quality of life. Chronic pain affects between one-third and one-half of the population of the UK, corresponding to just under 28 million adults**
Published at the Wounds UK conference in 2023, Medstrom has three case studies evidencing the use of Dolphin Therapy and reduction in analgesia. This is due to its unique mechanism of action that fully immerses and envelops patients into the support surface, maximising contact surface area and therefore alleviating any compression.
Ideal applications for pain management and comfort include end-of-life and hospices.
For over 10 years, Medstrom and its team of RGN Clinical Advisors have been collecting patient outcomes and testimonials to support the use of Dolphin Therapy fluid immersion simulation. This has accumulated to an evidence base of over 3,000+ outcomes and a vast amount of powerful peer and patient testimonials, confirming effectiveness of Dolphin Therapy for:
These outstanding and consistent outcomes have resulted in Dolphin Therapy being acknowledged as the only ‘step up’ option from dynamic mattresses in many healthcare organisations, rented as and when required, outside of any mattress contract in situ.
To read more about Dolphin Therapy outcomes, click here.
